Vanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTX

Vanguard Group Inc. grew its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 2.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,841,002 shares of the biopharmaceutical company’s stock after purchasing an additional 319,703 shares during the period. Vanguard Group Inc. owned about 9.98% of TG Therapeutics worth $472,220,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Royal Bank of Canada grew its stake in shares of TG Therapeutics by 16.4% in the 1st quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock valued at $2,985,000 after buying an additional 10,660 shares in the last quarter. NewEdge Advisors LLC raised its position in TG Therapeutics by 9.6% during the first quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 665 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in TG Therapeutics by 21.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after acquiring an additional 345,059 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in TG Therapeutics by 5.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock worth $11,319,000 after acquiring an additional 14,689 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in TG Therapeutics by 86.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 573 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $36.10 on Wednesday. The company has a current ratio of 4.10, a quick ratio of 3.29 and a debt-to-equity ratio of 0.38. The company has a fifty day simple moving average of $32.24 and a 200 day simple moving average of $31.49. The company has a market cap of $5.53 billion, a P/E ratio of 13.03 and a beta of 1.68. TG Therapeutics, Inc. has a 1 year low of $25.28 and a 1 year high of $40.99.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.06). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 1.32 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Zacks Research lowered shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, May 1st. Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. JPMorgan Chase & Co. reduced their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday. Finally, Wall Street Zen lowered TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.